Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib
{{output}}
Selpercatinib is a highly selective RET inhibitor with potent activity in RET-driven malignancies. Zoledronic acid is a standard bone-modifying agent for bone metastases, but its potential to induce hyperprogressive disease (HPD) is unclear. We present a 59-ye... ...
